Luca Sorrentino is a biotechnologist with a PhD in Biomolecular Sciences (Università degli Studi di Milano, 2015) and a master in Pharmaceutical Management (ISTUM, 2020).
During his academic career, he specialized in structure-based drug design projects. From 2016 to 2018, he worked in the Crystallography Unit of the Biophysics Institute (National Research Council, Milan) on the design and development of new potential anti-cancer drugs. From 2018 to 2021, he was a post-doc researcher at the Chemistry Department (Università degli Studi di Milano) and worked on the design of anti-microbial compounds targeting bacterial persistence. In July 2021, Luca joined the CheckmAb team as a biochemist researcher, working on the characterization of therapeutic targets and monoclonal antibodies for the development of novel cancer immunotherapies.